TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03071575

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-rubella (MR) vaccine at 6 and 9 months
Description: Arm A will receive MR vaccine dose at 6 and 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-rubella (MR) vaccine at 9 months
Description: Arm A will receive MR vaccine dose at 9 months of age
Study: NCT01290640

Intervention type: DEVICE
Intervention: DePuy fixed-bearing Total Condylar III (TC3) TKA

Intervention type: DEVICE
Intervention: DePuy PFC Rotating Platform TC3 TKA
Study: NCT01562405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg days 1,8,15,22; given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg daily on days 1-21
Study: NCT00933920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Study: NCT01025570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Bosutinib
Description: Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
Study: NCT01183130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliance monitoring with electronic device
Description: Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
Study: NCT02743546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvortuxizumab
Description: Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
Study: NCT03172091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eNose (electronic nose)
Description: Collection of exhaled breath for an immediate analysis by electronic nose

Intervention type: DEVICE
Group type: OTHER
Intervention: eNose (electronic nose)
Description: Collection of exhaled breath for an immediate analysis by electronic nose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrometry
Description: Collection of exhaled breath for an immediate analysis by mass spectrometry

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectrometry
Description: Collection of exhaled breath for an immediate analysis by mass spectrometry
Study: NCT02000011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive geriatric assessment (CGA)

Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive geriatric assessment (CGA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention plan (GIP)
Study: NCT03398265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Navigation (Intervention)
Description: Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
Study: NCT02833792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Mesenchymal Stem Cells and Lactated Riunger's Solution
Description: Intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT03908645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted bowel preparation quality scoring system
Description: After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional human scoring
Description: After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
Study: NCT01582737

Intervention type: DRUG
Intervention: Rivaroxaban(Xarelto, BAY59-7939)
Description: Patients treated with Xarelto under practical manner
Study: NCT01497821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 172
Description: AMG 172 is an antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 172
Description: AMG 172 is an antibody drug conjugate
Study: NCT04883840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin 10mg
Description: Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
Study: NCT03285958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS Intervention
Description: Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
Study: NCT01316952

Intervention type: DRUG
Intervention: Carvedilol immediate release only
Description: All dosages of carvedilol immediate release

Intervention type: DRUG
Intervention: Carvedilol extended release only
Description: All dosages of carvedilol extended release

Intervention type: DRUG
Intervention: Long acting β-blockers
Description: All dosages of LA propranolol and SA metoprolol

Intervention type: DRUG
Intervention: Other α1/β-adrenergic antagonists
Description: i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.

Intervention type: DRUG
Intervention: Short acting Non-selective β-blockers and short acting β1-Selective agents
Description: All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)

Intervention type: OTHER
Intervention: No β-blocker
Description: No β-blocker within the month prior to the index date
Study: NCT03050762

Intervention type: OTHER
Intervention: Data Collection
Description: Participant information collected from either source document or direct participant response.

Intervention type: BEHAVIORAL
Intervention: Follow Up
Description: Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
Study: NCT00663286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-110
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study: NCT00662376

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PreOP Booster (oral nutritional supplement, food for special medical purposes)
Description: 3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster (oral nutritional supplement, food for special medical purposes)
Description: 3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
Study: NCT03515174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care Program
Description: This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
Study: NCT01001546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based
Description: Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Clinic-Based
Description: Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
Study: NCT00287937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01329614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Study: NCT01982747

Intervention type: DRUG
Group type: OTHER
Intervention: MGN-Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo-MGN
Study: NCT02432846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intuvax (INN: ilixadencel)
Description: Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Cytostatic/cytotoxic drug: protein kinase inhibitor .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Cytostatic/cytotoxic drug: protein kinase inhibitor .
Study: NCT04585022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnum, Zimmer Biomet, Warsaw, IN

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recap, Zimmer Biomet, Warsaw, IN
Study: NCT01329614

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Study: NCT01912287

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT focused on Generalized Anxiety Disorder (12 sessions)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stress Education
Description: Active control group (12 sessions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 sessions, mindfulness components
Study: NCT02127567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online writing tool
Description: The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.

Intervention type: OTHER
Group type: OTHER
Intervention: writing with no specific support
Description: The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
Study: NCT03103919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesia-ONE™
Description: Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia-ONE™
Description: Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia-360™
Description: Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Description: All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
Study: NCT00941018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
Study: NCT01329614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Study: NCT00941018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
Study: NCT01329614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Study: NCT05909774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test with Atalante exoskeleton in continuous walk type
Description: The continuous walk is smoother and more physiologic than the push and swing walk
Study: NCT00758082

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paper support
Description: Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDA-phone + telemonitoring
Description: Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
Study: NCT03453684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Vancomycin
Description: Intravenous Vancomycin Administration
Study: NCT02963207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Sano's classification
Description: Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NICE classification
Description: Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.